Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

“…12 In January, 2013, the South African National Tuberculosis Programme, with the support of non-governmental and academic partners, established the Bedaquiline Clinical Access Programme so that patients with pre-extensively drug-resistant tuberculosis and extensively drug-resistant tuberculosis at specialised public health facilities in South Africa could receive bedaquiline. 13 Early results of the South African Bedaquiline Clinical Access Programme cohort showed high amounts of culture conversion and encouraging outcomes, including survival. 14 …”

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

“…1 The South African Medicine Control Council (MCC; Department of Health, Pretoria, South Africa) approved the BDQ Clinical Access Programme (BCAP) to treat XDR-or pre-XDR-TB patients (defined as MDR-TB with additional resistance to either a fluoroquinolone or a second-line injectable) in December 2012 to allow patients safe access to BDQ prior to registration. 7 Sirturo, from Janssen Pharmaceutica (Beerse, Belgium), was subsequently registered in South Africa in October 2014. To inform the roll-out of BDQ, especially among HIV-infected patients on ART, we present an interim cohort analysis of patients treated under BCAP.…”

Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa

“…Since 2011, treatment for XDR TB has been decentralized in South Africa, and as of June 2015, a total of 400 sites were treating patients who had drug-resistant TB ( 27 ). Treatment regimens have been fortified by the addition of bedaquiline, delamanid, linezolid, clofazamine, and levofloxacin ( 28 ). Therefore, patients with XDR TB might be able to receive 3–5 effective drugs.…”